Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673760 | 0.90 | GSK3B (0.68) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL12806427 | 0.90 | GSK3B (0.55) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL1673512 | 0.90 | GSK3B (0.68) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL1652103 | 0.90 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL13915177 | 0.89 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL12806690 | 0.88 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL13915175 | 0.88 | GSK3B (0.53) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL1651246 | 0.88 | GSK3B (0.69) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL1673592 | 0.87 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL13917301 | 0.87 | GSK3B (0.69) | GSK3BCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764650-B | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP | 2010-06-16 | — | — | CN | claimed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | claimed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | claimed |
| CN-1764650-A | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-04-26 | — | — | CN | claimed |
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | UNM RAINFOREST INNOVATIONS (US) | 2024-01-23 | — | — | US | disclosed |
| US-20200262916-A1 | Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES | STC UNM (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| CN-1764650-B | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP | 2010-06-16 | — | — | CN | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| CN-1764650-A | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-04-26 | — | — | CN | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262916-A1 | Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES | ATG7, MLST8, STX18 | GSK3B 3124/4885CYP2D6 4711/4885CYP1A2 4652/4885 |
| US-11878018-B1 | Phosphorylation of Syntaxin 17 by TBK1 controls autophagy initiation | STXBP1, TBK1, STX18 | GSK3B 152/4885CYP2D6 4836/4885CYP1A2 4808/4885 |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | GSK3B 265/4885CYP2D6 3086/4885CYP1A2 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.